Online inquiry

IVTScrip™ mRNA-Anti-CD22, ACD22-VCMMAE(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1471MR)

This product GTTS-WQ1471MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD22 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL), Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001185099.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 933
UniProt ID P20273
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD22, ACD22-VCMMAE(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ1471MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2256MR IVTScrip™ mRNA-Anti-F, ALX-0171(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ALX-0171
GTTS-WQ13316MR IVTScrip™ mRNA-Anti-TFPI, PF-06741086(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA PF-06741086
GTTS-WQ2405MR IVTScrip™ mRNA-Anti-CD3E&EPCAM, AMG 110(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG 110
GTTS-WQ2591MR IVTScrip™ mRNA-Anti-MPL, AMG 531(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AMG 531
GTTS-WQ9243MR IVTScrip™ mRNA-Anti-MUC1, IMMU-107(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IMMU-107
GTTS-WQ12345MR IVTScrip™ mRNA-Anti-TIGIT, MTIG-7192-A(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MTIG-7192-A
GTTS-WQ14945MR IVTScrip™ mRNA-Anti-PDCD1, SHR-1210(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA SHR-1210
GTTS-WQ13493MR IVTScrip™ mRNA-Anti-IgG-Fc, PRTX-100(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA PRTX-100
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW